Table 1.

CD22 and CD19 Expression on Patient Cells with Various Hematological Malignancies

Normal Periph. Blood (6 volunteers)		CLL (6 patients)		AML (6 patients)
CD19	CD22	CD19	CD22	CD19	CD22
4.2	7.2	76.2	38.5	3.8	5.0
6.6	8.7	89.1	90.9	0.6	0.4
7.3	7.3	66.6	58.1	0.4	1.0
6.4	7.2	38.9	27.5	1.8	3.6
9.2	9.3	87.7	78.7	1.6	9.9
4.1	4.4	80.5	75.7	0.4	0.4
Average
6.3	7.4	73.2	61.6	1.4	3.4

B-ALL (5 patients)		Lymphoma (12 patients)		T-ALL (2 patients)
CD19	CD22	CD19	CD22	CD19	CD22
27.1	20.6	16.1	13.0	3.7	4.2
88.4	76.5	81.3	50.2	3.5	3.6
100.0	64.2	18.4	19.0
86.5	5.3	23.2	21.0
93.2	97.1	23.7	23.0
		46.4	35.8
		98.7	83.0
		68.3	70.0
		37.4	6.9
		89.1	13.9
		69.6	46.6
		52.5	50.3
Average
79.0	52.7	52.1	36.1	3.6	3.9

Cell surface expression of either anti-CD22 or CD19 was determined by standard immunofluorescence with either RFB4-FITC or HD37-FITC. Cells were obtained from C-ALL, B-ALL, B lymphoma, control T-ALL, or control AML patients with Institutional Review Board approval as described in the methods. Data are calculated as percent positive cells relative to a known negative control. Normal enriched peripheral blood cells were obtained from healthy volunteers. Data points were averaged for each group.